[1. Dupuy, A., Simon, R.M. Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting. JNCI J. Natl. Cancer Inst. 2007,99, 147-157. https://doi.org/10.1093/jnci/djk01810.1093/jnci/djk01817227998]Search in Google Scholar
[2. Elisei, R., Viola, D., Torregrossa, L et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012,97, 4390-4398. https://doi.org/10.1210/jc.2012-177510.1210/jc.2012-177523066120]Search in Google Scholar
[3. Liu, C., Chen, T., Liu, Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2016,14, 241. https://doi.org/10.1186/s12957-016-0979-110.1186/s12957-016-0979-1501208427600854]Search in Google Scholar
[4. Wang, N., Xu, D., Sofiadis, A et al. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2014,99, E1571-9. https://doi.org/10.1210/jc.2014-115810.1210/jc.2014-1158420793124758186]Search in Google Scholar
[5. Nikiforov, Y.E., Nikiforova, M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011,7, 569-580. https://doi.org/10.1038/nrendo.2011.14210.1038/nrendo.2011.14221878896]Search in Google Scholar
[6. Romei, C., Ciampi, R., Faviana, P et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide sym-porter genes in papillary thyroid cancer. Endocr Relat Cancer. 2008,15, 511-520. https://doi.org/10.1677/erc-07-013010.1677/ERC-07-013018509003]Search in Google Scholar
[7. Riesco-Eizaguirre, G., Gutierrez-Martinez, P., Garcia-Cabezas, M.A et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006, 13, 257-269. https://doi.org/10.1677/erc.1.0111910.1677/erc.1.0111916601293]Search in Google Scholar
[8. George, J.R., Henderson, Y.C., Williams, M.D et al. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. J Clin Endocrinol Metab. 2015,100, E1550-9. https://doi.org/10.1210/jc.2015-269010.1210/jc.2015-2690466715826461266]Search in Google Scholar
[9. Eloy, C., Santos, J., Soares, P., Sobrinho-Simões, M. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 2011,459, 265.10.1007/s00428-011-1133-7]Search in Google Scholar
[10. Liu, R., Xing, M. Diagnostic and Prognostic TERT Promoter Mutations in Thyroid Fine Needle Aspiration Biopsy. Endocr. Relat. Cancer. 2014,21, 825.10.1530/ERC-14-0359]Search in Google Scholar
[11. Liu, X., Wu, G., Shan, Y et al. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell cycle. 2013,12, 1637-1638.10.4161/cc.24662]Search in Google Scholar
[12. Melo, M., da Rocha, A.G., Vinagre, J et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014,99, E754-65. https://doi.org/10.1210/jc.2013-373410.1210/jc.2013-3734419154824476079]Search in Google Scholar
[13. Avares, C., Melo, M., Cameselle-Teijeiro, J.M et al. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. 2016,174, R117. https://doi.org/10.1530/eje-15-060510.1530/EJE-15-060526510840]Search in Google Scholar
[14. Xing, M., Liu, R., Liu, X et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014, 32, 2718-2726. https://doi.org/10.1200/jco.2014.55.509410.1200/JCO.2014.55.5094414518325024077]Search in Google Scholar
[15. Muzza, M., Colombo, C., Rossi, S et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol. Cell. Endocrinol. 2015,399, 288-295.10.1016/j.mce.2014.10.019]Search in Google Scholar
[16. Kachuri, L., Latifovic, L., Liu, G., Hung, R.J. Systematic review of genetic variation in chromosome 5p15. 33 and telo-mere length as predictive and prognostic biomarkers for lung cancer. Cancer Epidemiol. Prev. Biomarkers. 2016,25, 1537-1549.10.1158/1055-9965.EPI-16-0200]Search in Google Scholar
[17. Killedar, A., Stutz, M.D., Sobinoff, A.P et al. A common cancer risk-associated allele in the hTERT locus encodes a dominant negative inhibitor of telomerase. PLoS Genet. 2015,11.10.1371/journal.pgen.1005286445997526053551]Search in Google Scholar
[18. Shen, N., Lu, Y., Wang, X et al. Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis. Onco-target. 2017,8, 50864-50872. https://doi.org/10.18632/onco-target.1514010.18632/oncotarget.15140]Search in Google Scholar
[19. Nencha, U., Rahimian, A., Giry, M et al. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. J. Neurooncol. 2016,126, 441-446.10.1007/s11060-015-1999-3]Search in Google Scholar
[20. Basolo, F., Torregrossa, L., Giannini, R et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 2010,95, 4197-4205.10.1210/jc.2010-0337]Search in Google Scholar
[21. Xing, M., Tufano, R.P., Tufaro, A.P et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2004,89, 2867-2872.10.1210/jc.2003-032050]Search in Google Scholar
[22. Tufano, R.P., Teixeira, G. V, Bishop, J et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Med. 2012,91, 274-286. https://doi.org/10.1097/MD.0b013e31826a9c7110.1097/MD.0b013e31826a9c7122932786]Search in Google Scholar
[23. Kim, J., Giuliano, A.E., Turner, R.R et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann. Surg. 2006,244, 799.10.1097/01.sla.0000224751.80858.13]Search in Google Scholar
[24. Yan, C., Huang, M., Li, X et al. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr. Connect. 2019,8, 988-996. https://doi.org/10.1530/EC-19-024610.1530/EC-19-0246665224431252408]Search in Google Scholar
[25. Xing, M., Alzahrani, A.S., Carson, K.A et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015,33, 42-50. https://doi.org/10.1200/jco.2014.56.825310.1200/JCO.2014.56.8253426825225332244]Search in Google Scholar
[26. Kebebew, E., Weng, J., Bauer, J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 2007,246, 461-466. https://doi.org/10.1097/SLA.0b013e318148563d10.1097/SLA.0b013e318148563d195935917717450]Search in Google Scholar
[27. Kurtulmus, N., Duren, M., Ince, U et al. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine. 2012,42, 404-410. https://doi.org/10.1007/s12020-012-9651-x10.1007/s12020-012-9651-x22426956]Search in Google Scholar
[28. Kim, S.K., Woo, J.-W., Lee, J.H et al. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr. Relat. Cancer. 2016,23, 27-34. https://doi.org/10.1530/ERC-15-040810.1530/ERC-15-040826598713]Search in Google Scholar
[29. Kim, T.H., Park, Y.J., Lim, J.A et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012,118, 1764-1773. https://doi.org/10.1002/cncr.2650010.1002/cncr.2650021882184]Search in Google Scholar
[30. Haugen, B.R. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017,123, 372-381. https://doi.org/10.1002/cncr.3036010.1002/cncr.3036027741354]Search in Google Scholar
[31. Henke, L.E., Pfeifer, J.D., Ma, C et al. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. Cancer Med. 2015,4, 791-799. https://doi.org/10.1002/cam4.41710.1002/cam4.417447220125712893]Search in Google Scholar
[32. Wang, T.S., Sosa, J.A. Thyroid surgery for differentiated thyroid cancer – recent advances and future directions. Nat. Rev. Endocrinol. 2018,14, 670-683. https://doi.org/10.1038/s41574-018-0080-710.1038/s41574-018-0080-730131586]Search in Google Scholar
[33. Li, G., Pan, T., Guo, D., Li, L.-C. Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example. Mol. Biol. Int. 2014,2014, 967565. https://doi.org/10.1155/2014/96756510.1155/2014/967565416765625276428]Search in Google Scholar
[34. Epstein, D.J. Cis-regulatory mutations in human disease. Brief. Funct. Genomic. Proteomic. 2009,8, 310-316. https://doi.org/10.1093/bfgp/elp02110.1093/bfgp/elp021274280319641089]Search in Google Scholar
[35. Heidenreich, B., Kumar, R. Altered TERT promoter and other genomic regulatory elements: occurrence and impact. 2017,141, 867-876. https://doi.org/10.1002/ijc.3073510.1002/ijc.3073528407294]Search in Google Scholar
[36. Ko, E., Seo, H.-W., Jung, E.S et al. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget. 2016,7, 684-699. https://doi.org/10.18632/oncotarget.633110.18632/oncotarget.6331480802626575952]Search in Google Scholar
[37. Rachakonda, P.S., Hosen, I., de Verdier, P.J et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. U. S. A. 2013,110, 17426-17431. https://doi.org/10.1073/pnas.131052211010.1073/pnas.1310522110380863324101484]Search in Google Scholar
[38. Hirokawa, T., Arimasu, Y., Chiba, T et al. Clinicopatho-logical significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma. Pathol. Int. 2020,70, 217-223. https://doi.org/10.1111/pin.1290010.1111/pin.1290031943527]Search in Google Scholar
[39. Argyropoulou, M., Veskoukis, A.S., Karanatsiou, P.-M et al. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population. Pathol. Oncol. Res. 2020,26, 347-354. https://doi.org/10.1007/s12253-018-0497-210.1007/s12253-018-0497-230361901]Search in Google Scholar
[40. Qasem, E., Murugan, A.K., Al-Hindi, H et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr. Relat. Cancer. 2015,22, 901-908. https://doi.org/10.1530/ERC-15-039610.1530/ERC-15-039626354077]Search in Google Scholar
[41. Huang, M., Yan, C., Xiao, J et al. Relevance and clinicopatho-logic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagn. Pathol. 2019,14, 74. https://doi.org/10.1186/s13000-019-0849-610.1186/s13000-019-0849-6662637831300059]Search in Google Scholar
[42. Vuong, H.G., Altibi, A.M.A., Duong, U.N.P., Hassell, L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin. Endocrinol. (Oxf). 2017, 87, 411-417. https://doi.org/10.1111/cen.1341310.1111/cen.1341328666074]Search in Google Scholar